ABVC revenueFY2025$296.0K
- FY YoY
- -41.9%
- 5Y CAGR
- -9.3%
ABVC revenue was $296.0K for fiscal 2025 (ended Dec 31, 2025), down 41.9% from fiscal 2024. Compound annual growth was -9.3% over 5 years. It rose in 3 of the last 7 fiscal years.
ABVC BioPharma Inc. (ABVC) financials
For fiscal 2025 (ended Dec 31, 2025), ABVC BioPharma Inc. reported $296.0K of revenue and -$7.91M of net income.
- Revenue, FY2025
- $296.0K
- Revenue growth, YoY
- -41.9%
- Net income, FY2025
- -$7.91M
- Net margin
- -2671.8%
- EPS, diluted, FY2025
- -$0.39
- Cash
- $31.9K
- P/S
- 87.48
- Market cap
- $25.9M
FY2018FY2025
FY2016FY2025
FY2021FY2023
ABVC revenue and earnings growth
ABVC net incomeQ2 2026-$736.9K
ABVC net income was -$736.9K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.26M a year earlier. For the full fiscal 2025 it was -$7.91M, compared with -$4.90M in fiscal 2024.
ABVC EPSQ2 2026-$0.03
ABVC diluted EPS was -$0.03 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$0.39.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.0K | $509.6K | $152.4K | $969.8K | $355.8K | $483.0K | $701.7K | $7.0K | - | - |
| Cost of revenue | - | $763 | $302.0K | $286.4K | $5.1K | $18.7K | $20.1K | $185.3K | - | $32 |
| Gross profit | - | $508.8K | -$149.6K | $683.4K | $350.7K | $464.3K | $681.6K | -$178.3K | - | -$32 |
| Research and development | $121.1K | $179.3K | $1.06M | $2.69M | $1.00M | $549.7K | $1.05M | $988.7K | $3.17M | $10.00M |
| Selling, general and admin | $2.89M | $2.26M | $5.37M | $6.07M | $5.75M | $4.27M | $3.07M | $1.59M | $811.7K | $599.3K |
| Operating income | -$7.15M | -$4.71M | -$6.77M | -$15.11M | -$11.71M | -$8.51M | -$3.46M | -$2.78M | -$4.14M | -$11.00M |
| Interest expense | $415.9K | $825.9K | $1.31M | $294.0K | $227.2K | $405.0K | $482.0K | $462.8K | $103.5K | $10.2K |
| Pre-tax income | -$8.35M | -$5.37M | -$8.02M | -$15.51M | -$11.21M | -$10.81M | -$4.01M | -$6.43M | -$4.24M | -$11.01M |
| Income tax | $24.2K | -$110.5K | $256.0K | $797.8K | $825.0K | -$220.4K | -$77.0K | -$365.1K | $830 | $836 |
| Net income | -$7.91M | -$4.90M | -$7.79M | -$16.42M | -$12.84M | -$10.59M | -$3.93M | -$6.06M | -$4.24M | -$11.01M |
| EPS, basic | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$5.10 | -$5.00 | -$2.10 | -$4.80 | -$0.20 | -$0.60 |
| EPS, diluted | -$0.39 | -$0.42 | -$1.80 | -$5.19 | -$5.10 | -$5.00 | -$2.10 | -$4.80 | -$0.20 | -$0.60 |
| Diluted shares | 20.1M | 11.7M | 4.3M | 3.2M | 2.5M | 2.0M | 1.7M | 1.2M | 21.3M | 19.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $681.5K | $863.8K | $716.8K | $1.39M | $6.57M | $5.00M | $160.4K | $242.8K | $406.8K | $173.5K |
| Short-term investments | $64.4K | $64.7K | $79.3K | $75.8K | $108.1K | - | - | - | - | - |
| Receivables | - | - | $1.5K | $98.3K | $280.7K | $159.7K | - | - | - | - |
| Inventory | - | - | - | - | $26.0K | - | - | $1.3K | - | - |
| Current assets | $2.50M | $2.18M | $1.66M | $2.99M | $7.65M | $6.17M | $878.2K | $566.5K | $2.64M | $173.5K |
| Total assets | $21.06M | $7.54M | $7.78M | $9.58M | $13.70M | $11.61M | $6.93M | $5.94M | $2.64M | $177.4K |
| Current liabilities | $6.16M | $6.56M | $6.10M | $5.54M | $3.69M | $4.84M | $6.81M | $10.99M | $4.40M | - |
| Short-term debt | $755.5K | $840.3K | $899.3K | $1.89M | $1.64M | $1.63M | $1.92M | $899.3K | - | - |
| Long-term debt | - | - | - | - | - | $2.50M | - | - | - | - |
| Total debt | - | - | - | - | - | $4.13M | - | - | - | - |
| Total liabilities | $7.76M | $6.82M | $6.53M | $6.34M | $4.83M | $8.94M | $7.05M | $11.28M | $4.40M | $6.56M |
| Shareholders' equity | $11.11M | $724.0K | $1.25M | $3.24M | $8.87M | $2.66M | -$124.8K | -$5.34M | $703.3K | -$6.38M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.99M | -$1.81M | -$4.19M | -$7.40M | -$7.60M | -$4.56M | -$3.13M | -$900.5K | -$1.49M | -$3.47M |
| Capital expenditures | - | - | $21.2K | $119.7K | $17.5K | - | - | - | - | - |
| Free cash flow | - | - | -$4.21M | -$7.52M | -$7.62M | - | - | - | - | - |
| Investing cash flow | -$1.21M | - | -$360.2K | -$1.72M | -$806.0K | -$225.4K | -$35.3K | -$156.4K | - | - |
| Financing cash flow | $4.64M | $1.98M | $3.87M | $4.01M | $10.00M | $9.57M | $3.09M | $896.9K | $1.56M | $2.65M |
| Stock-based compensation | $4.14M | $2.77M | $185.9K | $7.04M | $5.31M | $4.15M | $22.3K | $28.8K | $155.4K | $398.0K |
| Depreciation and amortization | - | - | - | $23.8K | $12.0K | - | - | - | - | - |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Sep 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -41.9% | 234.3% | -84.3% | 172.6% | -26.3% | -31.2% | 9988.0% | - | - | - |
| Gross margin | - | 99.9% | -98.1% | 70.5% | 98.6% | 96.1% | 97.1% | -2563.6% | - | - |
| Operating margin | -2416.0% | -923.3% | -4439.2% | -1558.5% | -3290.1% | -1760.9% | -492.9% | -40031.1% | - | - |
| Net margin | -2671.8% | -962.1% | -5109.3% | -1693.5% | -3608.5% | -2193.1% | -560.5% | -87184.2% | - | - |
| Free cash flow margin | - | - | -2760.6% | -775.2% | -2140.3% | - | - | - | - | - |
| Return on equity | -71.2% | -677.2% | -621.3% | -507.5% | -144.7% | -397.9% | - | - | -603.3% | - |
| Return on assets | -37.5% | -65.0% | -100.0% | -171.4% | -93.7% | -91.3% | -56.8% | -102.1% | -160.5% | -6206.8% |
| Current ratio | 0.41 | 0.33 | 0.27 | 0.54 | 2.07 | 1.27 | 0.13 | 0.05 | 0.60 | - |
| Debt to equity | - | - | - | - | - | 1.55 | - | - | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | $796.0K | - | - | $2.0K | $389.3K | $117.1K | $1.2K | $2.2K | $15.9K |
| Cost of revenue | - | - | - | - | - | - | $0 | $296 | $190 | $277 | $139.2K | $29.6K |
| Gross profit | - | - | - | $796.0K | - | - | $2.0K | $389.0K | $117.0K | $928 | -$137.0K | -$13.7K |
| Research and development | $22.7K | $33.1K | $29.1K | $29.9K | $33.3K | $28.9K | $32.0K | $37.8K | $40.4K | $69.1K | $72.2K | $141.3K |
| Selling, general and admin | $503.8K | $752.0K | $783.6K | $798.3K | $690.1K | $615.4K | $311.5K | $557.6K | $653.8K | $738.5K | $1.53M | $1.18M |
| Operating income | -$779.5K | -$1.57M | -$2.20M | -$1.96M | -$2.29M | -$693.0K | -$704.6K | -$302.3K | -$860.1K | -$2.84M | -$511.8K | -$2.15M |
| Interest expense | $42.3K | $49.4K | $32.6K | $31.0K | $129.4K | $223.0K | $216.7K | $220.4K | $207.1K | $181.7K | -$76.4K | $1.22M |
| Pre-tax income | -$810.5K | -$1.69M | -$3.02M | -$2.08M | -$2.31M | -$944.2K | -$796.5K | -$487.1K | -$1.16M | -$2.93M | -$525.0K | -$3.37M |
| Income tax | - | - | $0 | $527 | $23.6K | $0 | $0 | $355 | -$110.9K | $0 | $175.3K | -$999 |
| Net income | -$736.9K | -$1.56M | -$2.77M | -$2.04M | -$2.26M | -$842.1K | -$731.6K | -$394.8K | -$942.3K | -$2.83M | -$383.3K | -$3.32M |
| EPS, basic | -$0.03 | -$0.06 | - | -$0.09 | -$0.13 | -$0.06 | - | -$0.03 | -$0.08 | -$0.29 | - | -$0.82 |
| EPS, diluted | -$0.03 | -$0.06 | - | -$0.09 | -$0.13 | -$0.06 | - | -$0.03 | -$0.08 | -$0.29 | - | -$0.82 |
| Diluted shares | 26.1M | 25.4M | - | 23.3M | 17.4M | 15.0M | - | 12.4M | 11.3M | 9.7M | - | 4.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $31.9K | $140.3K | $681.5K | $192.1K | $1.08M | $759.6K | $863.8K | $769.9K | $742.8K | $659.0K | $716.8K | $1.12M |
| Short-term investments | $62.4K | $62.2K | $64.4K | $65.2K | $65.2K | $65.1K | $64.7K | $70.8K | $75.7K | $75.9K | $79.3K | $68.5K |
| Receivables | - | - | - | - | - | - | - | $1.5K | $1.5K | $1.5K | $1.5K | $1.5K |
| Inventory | - | - | - | $11.5K | $11.5K | $11.5K | - | - | - | - | - | - |
| Current assets | $411.7K | $648.8K | $2.50M | $3.31M | $2.77M | $1.47M | $2.18M | $2.17M | $2.31M | $1.79M | $1.66M | $2.49M |
| Total assets | $19.40M | $19.73M | $21.06M | $21.21M | $16.24M | $14.88M | $7.54M | $7.78M | $8.04M | $7.98M | $7.78M | $16.59M |
| Current liabilities | $5.69M | $5.39M | $6.16M | $6.54M | $6.53M | $6.73M | $6.56M | $6.25M | $6.25M | $6.18M | $6.10M | $5.36M |
| Short-term debt | $59.5K | $88.7K | $755.5K | $809.1K | $872.0K | $801.4K | $840.3K | $896.3K | $847.0K | $860.8K | $899.3K | $852.5K |
| Long-term debt | - | - | - | - | - | - | - | - | - | - | - | $1.65M |
| Total debt | - | - | - | $500.0K | - | - | - | - | - | - | - | $2.51M |
| Total liabilities | $7.13M | $6.90M | $7.76M | $6.72M | $6.75M | $6.92M | $6.82M | $6.44M | $6.50M | $6.52M | $6.53M | $7.53M |
| Shareholders' equity | $10.29M | $12.83M | $11.11M | $12.06M | $9.49M | $7.96M | $724.0K | $1.64M | $1.54M | $1.46M | $1.25M | $9.06M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$244.4K | -$894.2K | -$587.6K | -$964.7K | -$894.2K | -$539.8K | -$702.1K | $60.2K | -$211.4K | -$955.8K | -$430.5K | -$1.36M |
| Capital expenditures | - | - | - | - | - | - | - | - | - | - | $0 | - |
| Free cash flow | - | - | - | - | - | - | - | - | - | - | -$430.5K | - |
| Investing cash flow | -$101.5K | $47.1K | -$29.7K | -$513.4K | - | - | - | $44.8K | - | - | $154.2K | -$73.8K |
| Financing cash flow | $226.2K | -$342.2K | $1.08M | $1.20M | $1.93M | $428.8K | $335.8K | -$81.4K | $802.2K | $924.1K | $38.4K | $1.66M |
| Stock-based compensation | $253.0K | $787.4K | $1.39M | $1.14M | $1.57M | $48.8K | $363.1K | $95.9K | $282.9K | $2.03M | -$1.22M | $817.7K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | - | - | $7.5K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | 104.5% | - | - | -9.2% | 2350.7% | 1817.5% | -99.1% | -99.6% | -62.4% |
| Gross margin | - | - | - | 100.0% | - | - | 100.0% | 99.9% | 99.8% | 77.0% | -6329.8% | -86.4% |
| Operating margin | - | - | - | -246.8% | - | - | -35837.4% | -77.7% | -734.2% | -235539.8% | -23641.3% | -13566.3% |
| Net margin | - | - | - | -256.6% | - | - | -37211.3% | -101.4% | -804.4% | -235203.2% | -17705.7% | -20885.9% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - | -19882.8% | - |
| Current ratio | 0.07 | 0.12 | 0.41 | 0.51 | 0.42 | 0.22 | 0.33 | 0.35 | 0.37 | 0.29 | 0.27 | 0.46 |
| Debt to equity | - | - | - | 0.04 | - | - | - | - | - | - | - | 0.28 |
Source: XBRL data ABVC BioPharma Inc. files with the SEC, latest filing dated Aug 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-10, first reported Aug 14, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ABVC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ABVC | $296.0K | -41.9% | -$7.91M | -2671.8% | $25.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.28T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $655.56B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $509.50B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $362.53B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $308.99B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.75B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $196.57B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.45B |
ABVC FAQ
7 questionsWhat is ABVC revenue?
ABVC BioPharma Inc. (ABVC) reported $296.0K of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 41.9% from the year before.Is ABVC profitable?
No. ABVC BioPharma Inc. reported a net loss of $7.91M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does ABVC have?
ABVC BioPharma Inc. reported $31.9K in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is ABVC revenue growing?
ABVC BioPharma Inc.'s revenue changed -41.9% in fiscal 2025, to $296.0K. Its compound annual growth rate was -9.3% over 5 years.What is ABVC earnings per share?
Diluted earnings per share were -$0.39 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did ABVC last report financial results?
The latest statements here come from ABVC BioPharma Inc.'s 10-Q filed on Aug 12, 2026, covering the period ended Jun 30, 2026.Where does this ABVC financial data come from?
Quantisnow builds these statements from the structured XBRL data ABVC BioPharma Inc. files with the SEC. It is provided for information only and is not investment advice.